Altimmune (ALT) EBITDA Margin (2010 - 2025)
Altimmune (ALT) reported EBITDA Margin of 104884.62% for Q4 2025, up 36127538.0% year-over-year from N/an in Q4 2024, and up 72.39% on a QoQ basis from 379820.0% in Q3 2025.
Altimmune (ALT) has 16 years of EBITDA Margin data on file, last reported at 104884.62% in Q4 2025.
- Quarterly EBITDA Margin rose 36127538.0% year-over-year to 104884.62% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 214751.22% (up 26038878.0% YoY) and the FY2025 annual result came in at 214751.22%, up 26038878.0% from the prior year.
- EBITDA Margin rose to 104884.62% in Q4 2025 per ALT's latest filing, from 379820.0% in the prior quarter.
- Across five years, EBITDA Margin topped out at 728.99% in Q4 2021 and bottomed at 1182950.0% in Q3 2022.
- The 5-year median for EBITDA Margin is 178861.06% (2025), against an average of 264861.84%.
- The widest annual swing landed in 2022, when EBITDA Margin tumbled 116173987 bps; it then soared 117725525 bps in 2023.
- Tracing ALT's EBITDA Margin over 5 years: stood at 728.99% in 2021, then slumped by 11288 bps to 83015.38% in 2022, then declined by 3 bps to 85191.89% in 2023, then sank by 447 bps to 466160.0% in 2024, then soared by 78 bps to 104884.62% in 2025.
- Per Business Quant, the three latest ALT EBITDA Margin figures stand at 104884.62% (Q4 2025), 379820.0% (Q3 2025), and 443640.0% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -104,884.62% |
| Sep 30, 2025 | -379,820.00% |
| Jun 30, 2025 | -443,640.00% |
| Mar 31, 2025 | -392,100.00% |
| Dec 31, 2024 | -466,160.00% |
| Sep 30, 2024 | -449,960.00% |
| Jun 30, 2024 | -493,420.00% |
| Mar 31, 2024 | -491,020.00% |
| Dec 31, 2023 | -85,191.89% |
| Sep 30, 2023 | -5,694.75% |
| Jun 30, 2023 | -269,000.00% |
| Mar 31, 2023 | -94,990.48% |
| Dec 31, 2022 | -83,015.38% |
| Sep 30, 2022 | -1,182,950.00% |
| Jun 30, 2022 | -252,837.50% |
| Mar 31, 2022 | -60,718.75% |
| Dec 31, 2021 | -728.99% |
| Sep 30, 2021 | -21,210.13% |
| Jun 30, 2021 | -18,121.17% |
| Mar 31, 2021 | -1,773.15% |
| Dec 31, 2020 | -459.38% |
| Sep 30, 2020 | -605.20% |
| Jun 30, 2020 | -356.30% |
| Mar 31, 2020 | -177.07% |
| Dec 31, 2019 | -711.28% |
| Sep 30, 2019 | -1,695.77% |
| Jun 30, 2019 | -208.29% |
| Mar 31, 2019 | -70.96% |
| Dec 31, 2018 | -946.73% |
| Sep 30, 2018 | -89.25% |
| Jun 30, 2018 | -422.71% |
| Mar 31, 2018 | -95.06% |
| Dec 31, 2017 | -168.16% |
| Sep 30, 2017 | -673.64% |
| Jun 30, 2017 | -61.01% |
| Mar 31, 2017 | -1,334.89% |
| Dec 31, 2016 | -424.01% |
| Sep 30, 2016 | -123,771.69% |
| Jun 30, 2016 | -720.22% |
| Mar 31, 2016 | -120.98% |
| Dec 31, 2015 | -71.67% |
| Sep 30, 2015 | -140.46% |
| Jun 30, 2015 | -167.73% |
| Mar 31, 2015 | 16.95% |
| Dec 31, 2014 | -141.64% |
| Sep 30, 2014 | -411.34% |
| Jun 30, 2014 | -30.98% |
| Mar 31, 2014 | -63.11% |
| Dec 31, 2013 | -137.50% |
| Sep 30, 2013 | -90.44% |
| Jun 30, 2013 | -33.52% |
| Mar 31, 2013 | -16.03% |
| Dec 31, 2012 | -22.58% |
| Sep 30, 2012 | -25.66% |
| Jun 30, 2012 | -23.08% |
| Mar 31, 2012 | -25.87% |
| Dec 31, 2011 | -17.35% |
| Sep 30, 2011 | -57.45% |
| Jun 30, 2011 | -47.93% |
| Mar 31, 2011 | -71.63% |
| Dec 31, 2010 | -105.71% |
| Sep 30, 2010 | -53.89% |
| Jun 30, 2010 | -115.85% |